Antibody–drug conjugates for cancer therapy von Thomas, Anish, MD, Teicher, Beverly A, PhD, Hassan, Raffit, Dr

Volltext

Advances in Anticancer Immunotoxin Therapy von Alewine, Christine, Hassan, Raffit, Pastan, Ira

Volltext

Mesothelin Immunotherapy for Cancer: Ready for Prime Time? von Hassan, Raffit, Thomas, Anish, Alewine, Christine, Le, Dung T, Jaffee, Elizabeth M, Pastan, Ira

Volltext

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline von Kindler, Hedy L, Ismaila, Nofisat, Armato, 3rd, Samuel G, Bueno, Raphael, Hesdorffer, Mary, Jahan, Thierry, Jones, Clyde Michael, Miettinen, Markku, Pass, Harvey, Rimner, Andreas, Rusch, Valerie, Sterman, Daniel, Thomas, Anish, Hassan, Raffit

Volltext

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors von Hassan, Raffit, Blumenschein, Jr, George R, Moore, Kathleen N, Santin, Alessandro D, Kindler, Hedy L, Nemunaitis, John J, Seward, Shelly M, Thomas, Anish, Kim, Stella K, Rajagopalan, Prabhu, Walter, Annette O, Laurent, Dirk, Childs, Barrett H, Sarapa, Nenad, Elbi, Cem, Bendell, Johanna C

Volltext

Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response von Zhang, Jingli, Khanna, Swati, Jiang, Qun, Alewine, Christine, Miettinen, Markku, Pastan, Ira, Hassan, Raffit

Volltext

Immunotherapies for non-small-cell lung cancer and mesothelioma von Thomas, Anish, MD, Hassan, Raffit, MD

Volltext

Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients von Khanna, Swati, Graef, Suzanne, Mussai, Francis, Thomas, Anish, Wali, Neha, Yenidunya, Bahar Guliz, Yuan, Constance, Morrow, Betsy, Zhang, Jingli, Korangy, Firouzeh, Greten, Tim F, Steinberg, Seth M, Stetler-Stevenson, Maryalice, Middleton, Gary, De Santo, Carmela, Hassan, Raffit

Volltext

Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy von Hassan, Raffit, Morrow, Betsy, Thomas, Anish, Walsh, Tom, Lee, Ming K., Gulsuner, Suleyman, Gadiraju, Meghana, Panou, Vasiliki, Gao, Shaojian, Mian, Idrees, Khan, Javed, Raffeld, Mark, Patel, Snehal, Xi, Liqiang, Wei, Jun S., Hesdorffer, Mary, Zhang, Jingli, Calzone, Kathleen, Desai, Arpita, Padiernos, Emerson, Alewine, Christine, Schrump, David S., Steinberg, Seth M., Kindler, Hedy L., King, Mary-Claire, Churpek, Jane E.

Volltext

Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P von KREITMAN, Robert J, HASSAN, Raffit, FITZGERALD, David J, PASTAN, Ira

Volltext

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes von Liu, Wenhai, Onda, Masanori, Lee, Byungkook, Kreitman, Robert J, Hassan, Raffit, Xiang, Laiman, Pastan, Ira

Volltext

Immunotoxin treatment of cancer von Pastan, Ira, Hassan, Raffit, FitzGerald, David J, Kreitman, Robert J

Volltext

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading? von Cantini, Luca, Hassan, Raffit, Sterman, Daniel H, Aerts, Joachim G J V

Volltext

Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers von HASSAN, Raffit, BULLOCK, Susie, PREMKUMAR, Ahalya, KREITMAN, Robert J, KINDLER, Hedy, WILLINGHAM, Mark C, PASTAN, Ira

Volltext

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains von Carpenito, Carmine, Milone, Michael C, Hassan, Raffit, Simonet, Jacqueline C, Lakhal, Mehdi, Suhoski, Megan M, Varela-Rohena, Angel, Haines, Kathleen M, Heitjan, Daniel F, Albelda, Steven M, Carroll, Richard G, Riley, James L, Pastan, Ira, June, Carl H

Volltext

Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy von PASTAN, Ira, HASSAN, Raffit

Volltext

Scientific Advances and New Frontiers in Mesothelioma Therapeutics von Mutti, Luciano, Peikert, Tobias, Robinson, Bruce W.S., Scherpereel, Arnaud, Tsao, Anne S., de Perrot, Marc, Woodard, Gavitt A., Jablons, David M., Wiens, Jacinta, Hirsch, Fred R., Yang, Haining, Carbone, Michele, Thomas, Anish, Hassan, Raffit

Volltext

A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induc... von LE, Dung T, BROCKSTEDT, Dirk G, GIEDLIN, Martin, LOUIS, Jana-Lynn, SUGAR, Elizabeth A, PONS, Alice, COX, Andrea L, LEVINE, Jordana, LUCK MURPHY, Aimee, ILLEI, Peter, DUBENSKY, Thomas W, EIDEN, Joseph E, NIR-PAZ, Ran, JAFFEE, Elizabeth M, LAHERU, Daniel A, HAMPL, Johannes, MATHUR, Shruti, NEMUNAITIS, John, STERMAN, Daniel H, HASSAN, Raffit, LUTZ, Eric, MOYER, Bentley

Volltext

Consensus Report of the 2015 Weinman International Conference on Mesothelioma von Carbone, Michele, Kanodia, Shreya, Chao, Ann, Miller, Aubrey, Wali, Anil, Weissman, David, Adjei, Alex, Baumann, Francine, Boffetta, Paolo, Buck, Brenda, de Perrot, Marc, Dogan, A. Umran, Gavett, Steve, Gualtieri, Alessandro, Hassan, Raffit, Hesdorffer, Mary, Hirsch, Fred R., Larson, David, Mao, Weimin, Masten, Scott, Pass, Harvey I., Peto, Julian, Pira, Enrico, Steele, Ian, Tsao, Anne, Woodard, Gavitt Alida, Yang, Haining, Malik, Shakun

Volltext

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes von Mazor, Ronit, Eberle, Jaime A., Hu, Xiaobo, Vassall, Aaron N., Onda, Masanori, Beers, Richard, Lee, Elizabeth C., Kreitman, Robert J., Lee, Byungkook, Baker, David, King, Chris, Hassan, Raffit, Benhar, Itai, Ira

Volltext